Compare HSBC Holdings plc (HSBC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Recursion Pharmaceuticals Inc — how do they compare? HSBC Holdings plc trades at $104 (market cap $353.82B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: HSBC Holdings plc is far larger — about 195.5× Recursion Pharmaceuticals Inc's market cap, and HSBC Holdings plc pays a 3.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HSBC | RXRX | |
|---|---|---|
Market Cap | $353.82B | $1.81B |
Sector | Technology | Health |
52-Week High | $107.86 | $6.79 |
52-Week Low | $63.84 | $2.84 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC's stock trades at $103.88, up 0.54% today, with a bullish technical signal from moving averages and support near $103. Recent Q2 2026 earnings beat expectations with a 7% revenue rise to $19 billion (Defense World, 2026-08-06), and the company announced a $1 billion buyback (WSJ, 2026-08-04). Valuation metrics include a P/E of 14.74 and ROE of 12.44%, reflecting solid profitability.
The outlook is positive due to strong earnings momentum and shareholder returns, but risks include a recent analyst downgrade (Citi to 'neutral' on August 5, 2026) and exposure to Asian market volatility. With 38.1% of analysts rating it a buy, the stock offers growth potential tempered by competitive and regulatory headwinds.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
